A5064554548- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Infective Endocarditis Diagnosis and Management
- Pharmaceutical Economics and Policy
- Cardiovascular Function and Risk Factors
- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cancer, Lipids, and Metabolism
- Cardiac Health and Mental Health
- Pediatric health and respiratory diseases
- Diet and metabolism studies
- Respiratory and Cough-Related Research
- Cardiac pacing and defibrillation studies
- Aortic Disease and Treatment Approaches
- Long-Term Effects of COVID-19
- Mechanical Circulatory Support Devices
- Cardiac Ischemia and Reperfusion
- Peripheral Artery Disease Management
- COVID-19 and healthcare impacts
- Medication Adherence and Compliance
Stiftung Institut für Herzinfarktforschung
2010-2023
Klinikum Ludwigshafen
2015-2019
Saad Specialist Hospital
2018
University of Rhode Island
2018
MSD (UK) Limited (United Kingdom)
2018
King Faisal Specialist Hospital & Research Centre
2018
National Guard Health Affairs
2018
Armed Forces Hospital
2018
Merck (Japan)
2018
Merck & Co., Inc., Rahway, NJ, USA (United States)
2017
<h3>Background</h3> Significant aortic regurgitation (AR) is rare following surgical valve replacement and has been associated with worse outcome. Following transcatheter implantation (TAVI), AR common, but little known about its determinants effect on clinical <h3>Objective</h3> To evaluate early outcome risk factors possibly after TAVI. <h3>Methods</h3> Data were analysed from 690 patients severe stenosis treated TAVI enrolled in the prospective multicentre German interventions registry....
To determine predictors of permanent pacemaker (PPM) implantation up to 30 days after transcatheter aortic valve (TAVI) in a prospective multicenter registry.Conduction disorders requiring PPM are one the most common complications seen TAVI. Knowledge about possible may help decrease rate implantations.In total, 1347 consecutive patients who underwent TAVI 22 centers were prospectively enrolled German interventions registry. Both Medtronic CoreValve™ and Edwards Sapien™ valves implanted....
The purpose of this study was to evaluate the efficacy and outcome transcatheter aortic valve implantation (TAVI) in patients with low-flow, low-gradient stenosis (LG-AS). Patients LG-AS have a poor prognosis medical treatment high risk for surgical replacement. Between January 2009 June 2010, total 1,302 underwent TAVI severe AS were prospectively included multicenter German registry. present 149 (11.4%; mean age: 80.2 ± 6.3 years). In subgroup, EuroSCORE significantly higher (26.8 16.6 vs....
Background Patients with coronary heart disease (CHD) and survivors of acute syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. Design The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS CHD patients. Data seven...
Background As mortality due to cardiovascular disease increases throughout the world, accurate data on risk factors such as hyperlipidemia are required. This is lacking in Asia-Pacific region. Design The observational Dyslipidemia International Study (DYSIS) II was established quantify extent of adults with acute and stable coronary heart globally. Methods Patients or hospitalised an syndrome were enrolled across nine countries from July 2013 October 2014. Lipid-lowering therapy low-density...
Familial hypercholesterolemia (FH) is a life-threatening disease, characterized by elevated LDL-C levels and premature, increased risk of coronary heart disease (CHD) that globally underdiagnosed. The percentage patients with possible or probable FH in various countries was examined the Dyslipidemia International Study (DYSIS).DYSIS multinational, cross-sectional observational study 54,811 adult outpatients treated statin therapy. percentages high LDL-C, FH, were assessed using Dutch scoring...
Objectives Transcatheter aortic valve implantation (TAVI) is an emerging technology in patients with severe stenosis. Background Whether the degree of calcification impacts outcome after TAVI has not been thoroughly evaluated. Methods We analyzed data from prospective multicenter German registry, including 1,365 as July 2010. Patients were divided into three groups, based on calcification: mild ( n = 67), moderate 392), and 906) calcification, determined by visual estimation operator....
Data presented here refer to 57,885 patients on lipid-lowering statin therapy from the Dyslipidaemia International Study (DYSIS) registry. Subjects were divided into 3 discrete subsets: those at very high-risk, and non-high-risk for cardiovascular events, with assigned low density lipoprotein cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl 115 respectively. Overall, highest proportion meeting their LDL-C target was seen in UAE Kuwait (49.5%), while lowest Germany (14.3%). The smallest...
Aim: Metabolic syndrome (MetS) is a clustering of factors that are associated with increased cardiovascular risk. We aimed to investigate the proportion patients MetS in undergoing cardiac rehabilitation (CR), and describe differences between compared those without regard (1) patient characteristics including demographics, risk factors, comorbidities, (2) factor management drug treatment, (3) control status at entry CR discharge from CR. Methods: Post-hoc analysis data 27,904 inpatients...
A high body mass index (BMI) is associated with increased cardiovascular risk. We sought to identify whether BMI influences the choice of lipid-lowering treatment in a large, real-world cohort 52 916 patients treated statins. The Dyslipidemia International Study (DYSIS) cross-sectional, observational, multicentre study statin-treated ≥45 years age from 30 countries; 1.1% were underweight (BMI < 18.5 kg/m2 ), 33.1% had normal weight 18.5-24.9 41.5% overweight 25-29.9 17.1% class I obesity...
Current European guidelines recommend treatment with lipid-lowering therapy (LLT) to a low-density lipoprotein cholesterol (LDL-C) target of < 70 mg/dl for patients at very high risk. LDL-C attainment and use LLTs in these Greece is not known.The Dyslipidemia International Study (DYSIS) II was multicenter observational study. The coronary heart disease (CHD) cohort divided into two groups based on status (on LLT ≥ 3 months or LLT). acute syndrome (ACS) evaluated the time admission again 120...
The aim of this study was to evaluate under target rates low-density lipoprotein-cholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute syndrome (ACS) real world practice.Dyslipidemia International Study II international observational CAD ACS. Lipid profiles and use lipid-lowering therapy (LLT) were documented at enrollment, for the ACS cohort, 4 months follow-up recommended. Rates LDL-C as per European guidelines, evaluated, multivariate regression...
Dyslipidaemia is a major risk factor for coronary heart disease (CHD). There lack of data on the extent lipid abnormalities and lipid-lowering therapy (LLT) in Singapore.The Dyslipidemia International Study (DYSIS) II was multinational observational study patients with stable CHD hospitalised an acute syndrome (ACS). A full profile use LLT were documented at baseline, ACS cohort, four months post-hospitalisation.325 recruited from sites Singapore; 199 had 126 ACS. At 96.5% cohort 66.4% being...
Careful management of lipid abnormalities in patients with coronary heart disease (CHD) or an acute syndrome (ACS) can reduce the risk recurrent cardiovascular events. The extent hyperlipidemia these very high-risk United Arab Emirates (UAE), along treatment strategies employed, is not clear.The Dyslipidemia International Study II was a multinational observational analysis carried out from 2012 to 2014. Patients were enrolled if they had either stable CHD ACS. Patient characteristics,...
DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 (93.8%) on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent 25 mg per day and 10.5% received ezetimibe combination with statin. low-density lipoprotein cholesterol (LDL-C) level 88 mg/dL, 29.4% of displaying below the 70 mg/dL target very high-risk subjects. While more than 90% drugs,...